Novartis registers two Phase I trials: TRB191 in SCLC and XEP527 in schizophrenia
Both studies were first posted November 2, 2026, and remain not yet recruiting as Novartis plans early-stage work in lung cancer and schizophrenia.
Novartis Pharmaceuticals posted two new Phase I trial registrations this week, both listed as not yet recruiting.
- TRB191 (NCT07908667) is a Phase I, open-label, multi-center, first-in-human study in patients with extensive-stage small cell lung cancer, sponsored by Novartis Pharmaceuticals. The purpose of the study is to characterize the safety, tolerability, pharmacokinetics, immunogenicity and preliminary anti-tumor activity and to determine a recommended dose of TRB191 in patients with extensive-stage small cell lung cancer, in a first-in-human design.1 The trial plans to enroll 120 participants (estimated)1, with an estimated start date of 2026-11-17 and estimated primary completion of 2030-08-06.
- XEP527 (NCT07908680) is a Phase I, randomized, placebo-controlled multiple ascending dose study in patients with stable schizophrenia, sponsored by Novartis Pharmaceuticals. The study is designed to assess the safety and tolerability of the effects of XEP527, with particular emphasis on disease status and its compatibility with the standard of care in patients with stable schizophrenia.2 The trial plans to enroll 36 participants (estimated)2 across three dosing cohorts, with an estimated start date of 2026-11-04 and estimated primary completion of 2028-03-06.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.